NCT03371329 is a Phase 1 clinical trial of MSC in Hemorrhagic Stroke, sponsored by Mayo Clinic.

Who is sponsoring NCT03371329?

NCT03371329 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03371329?

Interventions in NCT03371329: MSC.

What condition does NCT03371329 study?

NCT03371329 studies Hemorrhagic Stroke, Intracerebral Hemorrhage.

Is NCT03371329 still recruiting?

NCT03371329 is currently completed. Last updated 21 December 2020.

Last reviewed 2020-12-21 · How we verify

NCT03371329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage

Completed Phase 1 Last updated 21 December 2020

What this trial tests

Phase 1 trial testing MSC in Hemorrhagic Stroke in 9 participants. Completed in 9 October 2020.

Timeline

12 December 2017

Primary endpoint
9 October 2020

9 October 2020

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	12 December 2017
Primary completion	9 October 2020
Estimated completion	9 October 2020
Sites	1 location across United States

Drugs / interventions tested

MSC — full drug profile →

Conditions studied

Hemorrhagic Stroke — all drugs for Hemorrhagic Stroke →
Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Hemorrhagic Stroke or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of acute spontaneous hemorrhagic stroke.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?
Galderisi U, Peluso G, Di Bernardo G. · · 2022 · cited 175× · PMID 34398443 · DOI 10.1007/s12015-021-10231-w
Differentiation of Human Mesenchymal Stem Cells towards Neuronal Lineage: Clinical Trials in Nervous System Disorders.
Hernández R, Jiménez-Luna C, Perales-Adán J, Perazzoli G, et al · · 2020 · cited 95× · PMID 31649208 · DOI 10.4062/biomolther.2019.065
Cell-Based and Exosome Therapy in Diabetic Stroke.
Venkat P, Chopp M, Chen J. · · 2018 · cited 47× · PMID 29498242 · DOI 10.1002/sctm.18-0014
Cell-Based Therapies for Stroke: Are We There Yet?
Krause M, Phan TG, Ma H, Sobey CG, et al · · 2019 · cited 37× · PMID 31293500 · DOI 10.3389/fneur.2019.00656
Taking central nervous system regenerative therapies to the clinic: curing rodents <i>versus</i> nonhuman primates <i>versus</i> humans.
Tsintou M, Dalamagkas K, Makris N. · · 2020 · cited 26× · PMID 31571651 · DOI 10.4103/1673-5374.266048
Locoregional delivery of stem cell-based therapies.
Ng NN, Thakor AS. · · 2020 · cited 24× · PMID 32522806 · DOI 10.1126/scitranslmed.aba4564
Mesenchymal Stem Cell Application and Its Therapeutic Mechanisms in Intracerebral Hemorrhage.
Yang G, Fan X, Mazhar M, Yang S, et al · · 2022 · cited 22× · PMID 35769327 · DOI 10.3389/fncel.2022.898497
Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.
Soares MBP, Gonçalves RGJ, Vasques JF, da Silva-Junior AJ, et al · · 2022 · cited 16× · PMID 35782379 · DOI 10.3389/fnmol.2022.883378

Verify or expand the search:

Other trials of MSC

Trials testing the same drug.

NCT06823063 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD · Phase 1 · not yet recruiting
NCT06813157 — Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia · NA · recruiting
NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown

Other recruiting trials for Hemorrhagic Stroke

Currently open trials in the same condition.

NCT07236216 — Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Moto · NA · recruiting
NCT07224178 — Left Atrial Strain and Cryptogenic Stroke · recruiting
NCT06940635 — Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stro · NA · recruiting
NCT06999122 — Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected · recruiting
NCT06094478 — Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition · NA · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03371329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 21 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03371329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing